Close Menu

Regulus

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs
Patent Number: 8,133,876
Filed: Dec. 30, 2008
Lead Inventor: Frank Bennett, Regulus Therapeutics

Title: Method and Medicament for Inhibiting the Expression of a Given Gene
Patent Number: 8,114,851
Filed: Oct. 31, 2007
Lead Inventor: Roland Kreutzer, Alnylam Pharmaceuticals

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs
Patent Number: 8,110,558
Filed: Dec. 31, 2008
Lead Inventor: Frank Bennett, Regulus Therapeutics

Regulus Therapeutics said this week that that Australian Patent Office has recently granted certain claims in a company-controlled patent family covering the use of microRNA-122 in treating hepatitis C.

The discovery triggered a milestone payment of an undisclosed amount, Regulus said.

Gregory Hannon

Mice treated with a miR-33 antagonist displayed increased HDL-C, enhanced reverse cholesterol transport to the plasma, liver, and feces, and reductions in plaque size and lipid content.

Pages

A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.

Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.

Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.

In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.